Oncotarget

Research Papers:

Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype

Karolina Gołąb _, Randall Grose, Veronica Placencia, Amittha Wickrema, Julia Solomina, Martin Tibudan, Evelyn Konsur, Kamil Ciepły, Natalia Marek- Trzonkowska, Piotr Trzonkowski, J. Michael Millis, John Fung and Piotr Witkowski

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:9728-9740. https://doi.org/10.18632/oncotarget.23887

Metrics: PDF 2378 views  |   HTML 4071 views  |   ?  


Abstract

Karolina Gołąb1, Randall Grose2, Veronica Placencia3, Amittha Wickrema3, Julia Solomina1, Martin Tibudan1, Evelyn Konsur1, Kamil Ciepły1, Natalia Marek-Trzonkowska4, Piotr Trzonkowski5, J. Michael Millis1, John Fung1 and Piotr Witkowski1

1Department of Surgery, University of Chicago, Chicago, IL, USA

2South Australian Health and Medical Research Institute, University of Adelaide, SA, Australia

3Department of Medicine, Hematology-Oncology, Cancer Research Center, University of Chicago, Chicago, IL, USA

4Department of Family Medicine, Medical University of Gdańsk, Gdańsk, Poland

5Department of Clinical Immunology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland

Correspondence to:

Piotr Witkowski, email: [email protected]

Keywords: regulatory T cells (Tregs); cell banking strategies; effect of cryopreservation; Treg-based therapies

Received: February 24, 2017     Accepted: November 10, 2017     Published: January 03, 2018

ABSTRACT

The first clinical trials with adoptive Treg therapy have shown safety and potential efficacy. Feasibility of such therapy could be improved if cells are cryopreserved and stored until optimal timing for infusion.

Herein, we report the evaluation of two cell-banking strategies for Treg therapy: 1) cryopreservation of CD4+ cells for subsequent Treg isolation/expansion and 2) cryopreservation of ex-vivo expanded Tregs (CD4+CD25hiCD127lo/- cells). First, we checked how cryopreservation affects cell viability and Treg markers expression. Then, we performed Treg isolation/expansion with the final products release testing.

We observed substantial decrease in cell number recovery after thawing and overnight culture. This observation might be explained by the high percentage of necrotic and apoptotic cells found just after thawing. Furthermore, we noticed fluctuations in percentage of CD4+CD25hiCD127- and CD4+FoxP3+ cells obtained from cryopreserved CD4+ as well as Treg cells. However, after re-stimulation Tregs expanded well, presented a stable phenotype and fulfilled the release criteria at the end of expansions.

Cryopreservation of CD4+ cells for subsequent Treg isolation/expansion and cryopreservation of expanded Tregs with re-stimulation and expansion after thawing, are promising solutions to overcome detrimental effects of cryopreservation. Both of these cell-banking strategies for Treg therapy can be applied when designing new clinical trials.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23887